SILVER SPRING, Md., BOSTON and SOUTH SAN FRANCISCO, Calif., May 18 /PRNewswire/ -- The Pulmonary Hypertension Association (PHA), Tufts Medical Center, and Actelion Pharmaceuticals US, Inc., today announced Dr. Nicholas Hill of Tufts Medical Center as the recipient of the 2009 PHA Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care. The grant, in the amount of $50,000, will be awarded to Tufts Medical Center to support continued excellence in care for patients with PAH. The award, supported by an unrestricted educational grant from Actelion, was presented at the 2009 International Conference of the American Thoracic Society (ATS) in San Diego.
"Dr. Hill has dedicated his career to improving the lives of patients with PAH," said Michael McGoon, MD, Professor of Medicine and Consultant in Cardiology at the Mayo Clinic College of Medicine and chair of the Independent Award Selection Committee. "His passionate desire to better the lives of patients, and his consistent excellence in PAH clinical research and medical, epitomize the spirit of the PHA. We are pleased to present this award in recognition of his devotion."
The PHA Award of Excellence in PAH Care is designed to honor and acknowledge healthcare professionals who are committed to improving outcomes for patients with PAH. It is awarded annually to outstanding care providers for clinical practice excellence in the area of PAH.
"The Pulmonary Hypertension Association Award of Excellence encourages advances in both patient care and research in the area of PAH, a serious condition that continues to be under-recognized and under-treated," said Rino Aldrighetti, president of PHA. "In recent years, the picture for patients with PAH has brightened due to improved patient care and treatment options. PHA believes that this annual award - in conjunction with its significant financial support for the recipient's work - shines a spotlight on this disease and contributes to ongoing development of effective PAH therapies. We congratulate Dr. Hill for his long history of achievements on behalf of PH patients and are pleased to provide this well-deserved recognition."
This year's award recipient was selected by the 2009 PHA Award Steering Committee, comprised of: Michael McGoon, MD, professor of medicine at the Mayo Clinic College of Medicine and consultant to the Division of Cardiovascular Disease at the Mayo Clinic, chair of the PHA Award Steering Committee; David Badesch, MD, professor of medicine in the Divisions of Pulmonary Sciences and Critical Care Medicine, and Cardiology, and the clinical director of the Pulmonary Hypertension Center at the
About Dr. Hill
Nicholas S. Hill, M.D. is chief of the Pulmonary, Critical Care and Sleep Division at Tufts Medical Center in Boston, professor of medicine at
Dr. Hill currently serves as ATS secretary-treasurer and will serve as ATS president from 2011 to 2012. Dr. Hill is a member of the Strategic Planning Committee and the Assembly on Critical Care's Planning and Program Committees. He has served on the editorial board of the American Journal of Respiratory and Critical Care Medicine, chaired the Program Committees of the Assemblies on Pulmonary Circulation and Critical Care and served on the Research Review and Coordinating Committees and the Council of Chapter Representatives.
About the Pulmonary Hypertension Association
The Pulmonary Hypertension Association (PHA) is dedicated to finding ways to prevent and cure pulmonary hypertension, and to provide hope for the pulmonary hypertension community through support, education, advocacy and awareness. The vision of PHA is to improve the lives of those affected by pulmonary hypertension. More information about PHA is available at www.phassociation.org.
About Actelion Pharmaceuticals
Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer(R), an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer(R) through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union, Japan, Canada, Australia and Switzerland. Actelion, founded in late 1997, is a leading player in innovative science related to the endothelium - the single layer of cells separating every blood vessel from the blood stream. Actelion's over 2000 employees focus on the discovery, development and marketing of innovative drugs for significant unmet medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI(R)).
Tufts Medical Center is an exceptional, not-for-profit, 451-bed academic medical center that is home to both a full-service hospital for adults and Floating Hospital for Children. Conveniently located in downtown Boston, the Medical Center is the principal teaching hospital for
|SOURCE Pulmonary Hypertension Association; Tufts Medical Center; Actelion Pharmaceuticals US, Inc.|
Copyright©2009 PR Newswire.
All rights reserved